Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.

doi:10.18632/oncotarget.12950

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.

Oncotarget - 15 Nov 2016

Clatot Florian, Perdrix Anne, Augusto Laetitia, Beaussire Ludivine, Delacour Julien, Calbrix Céline, Sefrioui David, Viailly Pierre-Julien, Bubenheim Michael, Moldovan Cristian, Alexandru Cristina, Tennevet Isabelle, Rigal Olivier, Guillemet Cécile, Leheurteur Marianne, Gouérant Sophie, Petrau Camille, Théry Jean-Christophe, Picquenot Jean-Michel, Veyret Corinne, Frébourg Thierry, Jardin Fabrice, Sarafan-Vasseur Nasrin, Di Fiore Frédéric

Abstract excerpt

PURPOSE: To assess the prognostic and predictive value of circulating ESR1 mutation and its kinetics before and after progression on aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: ESR1 circulating D538G and Y537S/N/C mutations were retrospectively analyzed by digital droplet PCR after first-line AI failure in patients treated consecutively from 2010 to 2012 for hormone receptor-positive metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Disease Progression

Share to DNA, Neoplasm

Share to Estrogen Receptor alpha

Share to Follow-Up Studies

Share to Neoplasm Metastasis

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27801670
DOI: 10.18632/oncotarget.12950
PMCID: PMC5342678

Genes

ESR1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.PMID 27801670Read ↗

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.Semantic proximity Read ↗

Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.Semantic proximity Read ↗

Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerSemantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.Semantic proximity Read ↗

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerSemantic proximity Read ↗

[Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer].Semantic proximity Read ↗

Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot StudySemantic proximity Read ↗

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.Semantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.